| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Lariam | Roche | Roche Products | 250mg | 8 | Tablet | per tablet | KES 3,917.00 |
| Mefliam | Cipla Ltd. | Surgipharm Ltd | 250mg | 4 | Tablet | per tablet | KES 330.00 |
| Mevax | Ajanta Pharmaceuticals Ltd | Simba Pharmaceutical Ltd. | 250mg | 6 | Tablet | per tablet | KES 390.00 |
| Meflotas | Intas Pharmaceuticals Ltd | Medisel Kenya Ltd | 250mg | 4 | Tablet | per tablet | KES 250.00 |
| Mephaquin | Acino – Switzerland | Goodman Agencies Ltd | 250mg | 4 | Tablet | per tablet | KES 860.00 |
| Mefloquine More info | |
|---|---|
| Mode Of Action | May inhibit meroThey are also thought to inhibit heme polymerase activity resulting in accumulation of free heme, which is toxic to the parasites. |
| Drug Indication | Prophylaxis and treatment of malaria resistant to other drugs. |
| Precautions | Increased risk of convulsions in epileptics, contraceptives during prophylaxis and for 3 months following last dose period, perform liver function tests, cardiac and opthalmological functions, cardiac conduction disturbances, unexplained depression or anxiety. |
| Contra-Indications | Pregnancy, lactation, history of psychiatric disorders when quinine has been used. Impaired hepatic and renal functions, children with BM of less than 5kg. |
| Side Effects | Anorexia, nausea and vomiting, abdominal pain, diarrhoea, headache, bradycardia, neuropsychiatric disorders, rashes, pruritis, paraesthesia, general weakness, hair loss, fever, chills, muscle weakness and cramps. Erythema, myalgia, arthralgia. |
| Dosage | 20mg/kg (of the base) STAT or 10mg/kg STAT, then 10mg/kg after 6-8hrs. Prophylaxis: 1 tab weekly from 1 week before travelling and for at least 6 weeks after travelling. |
| Pregnancy Category | Category B3 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals show evidence of an increased occurrence of foetal damage, the significance of which is uncertain in human |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Anti-Malarials |